Arcutis Biotherapeutics Inc Announces Positive Topline Data from Phase 2 Seborrheic Dermatitis- Corporate Call Transcript
Good day, ladies and gentlemen, and welcome to the Arcutis conference call. As a reminder, this conference call is being recorded.
I would now like to introduce your host for today's conference, Ms. Heather Armstrong, Vice President of Investor Relations and Corporate Communications. You may begin.
Thank you. Good morning and welcome to our conference call and webcast to discuss our positive topline data from our Phase 2 clinical trial evaluating topical roflumilast foam as a potential treatment for seborrheic dermatitis also referred to as seb derm.
The slides viewed in today's webcast can be found under events and presentations in the investor section of our website at arcutis.com.
I'm joined on the call today by Frank Watanabe, President and CEO; Dr. Patrick Burnett, Chief Medical Officer; Dr. Matthew Zirwas, founder of the Bexley Dermatology Research Clinic and an investigator in the trial; Ken Lock, Chief Commercial Officer; and John Smither, CFO.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |